GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner
暂无分享,去创建一个
Bi-Jun Huang | Hao Hu | C. Qian | Y. Mei | F. Lin | Li-xia Peng | Si-Ting Lin | Y. Lang | Fei-Fei Luo | Yu-Jie Xie | Tie-jun Huang | Xin-ke Zhang | Hong-Fa Xu | Hu Liang
[1] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[2] Wanqing Chen,et al. Interactions between life expectancy and the incidence and mortality rates of cancer in China: a population-based cluster analysis , 2018, Cancer communications.
[3] C. Cui,et al. High G2 and S‐phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis , 2018, Cancer science.
[4] Joshua M. Stuart,et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. , 2018, Cell.
[5] J. R. Daum,et al. GTSE1 regulates spindle microtubule dynamics to control Aurora B kinase and Kif4A chromokinesin on chromosome arms , 2017, The Journal of cell biology.
[6] Eberhard Korsching,et al. Interlaboratory variability of Ki67 staining in breast cancer. , 2017, European Journal of Cancer.
[7] C. Qian. At-home cancer screening: a solution for China and other developing countries with a large population and limited number of healthcare practitioners , 2017, Chinese journal of cancer.
[8] Yanlin Huang,et al. GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis , 2017, Scientific Reports.
[9] M. Brackstone,et al. Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients , 2017, Supportive Care in Cancer.
[10] Monte D. Martin,et al. GTSE1: a novel TEAD4-E2F1 target gene involved in cell protrusions formation in triple-negative breast cancer cell models. , 2017, OncoTarget.
[11] B. Short. GTSE1 leads cancer cells into CIN , 2016, The Journal of cell biology.
[12] I. Ellis,et al. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer , 2016, Diagnostic Pathology.
[13] Ansar Karimian,et al. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. , 2016, DNA repair.
[14] Q. Ye,et al. Silencing GTSE-1 expression inhibits proliferation and invasion of hepatocellular carcinoma cells , 2016, Cell Biology and Toxicology.
[15] Joachim L. Schultze,et al. Web-TCGA: an online platform for integrated analysis of molecular cancer data sets , 2016, BMC Bioinformatics.
[16] A. Arance,et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.
[17] Hanlee P. Ji,et al. The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical–genomic driver associations , 2015, Genome Medicine.
[18] S. André,et al. Aneuploidy identifies subsets of patients with poor clinical outcome in grade 1 and grade 2 breast cancer. , 2015, Breast.
[19] W. Yong,et al. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells , 2015, BMC Cancer.
[20] Marius Raica,et al. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. , 2015, Anticancer research.
[21] Chirayu Pankaj Goswami,et al. PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.
[22] E. Hirsch,et al. PI3K/AKT signaling pathway and cancer: an updated review , 2014, Annals of medicine.
[23] Karin M. Verspoor,et al. Big Data in Medicine Is Driving Big Changes , 2014, Yearbook of Medical Informatics.
[24] Stephen L. Abrams,et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention , 2014, Oncotarget.
[25] M. Biffoni,et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells , 2014, Oncogene.
[26] J. Chen,et al. Alternative splicing in cancer: implications for biology and therapy , 2014, Oncogene.
[27] Manuel Rodrigues,et al. Place des technologies de séquençage haut débit en oncologie , 2013 .
[28] M. Rodrigues,et al. [Role of high-throughput sequencing in oncology]. , 2013, Bulletin du cancer.
[29] A. Hyman,et al. GTSE1 Is a Microtubule Plus-End Tracking Protein That Regulates EB1-Dependent Cell Migration , 2012, PloS one.
[30] M. Campone,et al. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer , 2012, Breast Cancer Research and Treatment.
[31] Jannik N. Andersen,et al. Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.
[32] J. Xing,et al. Up-regulation of GTSE1 lacks a relationship with clinical data in lung cancer. , 2011, Asian Pacific journal of cancer prevention : APJCP.
[33] Shu Ichihara,et al. Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.
[34] Jorge S. Reis-Filho,et al. Histological types of breast cancer: How special are they? , 2010, Molecular oncology.
[35] C. Schneider,et al. Human GTSE-1 Regulates p21CIP1/WAF1 Stability Conferring Resistance to Paclitaxel Treatment* , 2009, The Journal of Biological Chemistry.
[36] J. Reis-Filho,et al. Histological and molecular types of breast cancer: is there a unifying taxonomy? , 2009, Nature Reviews Clinical Oncology.
[37] James M. Roberts,et al. CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .
[38] K. Raj,et al. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death , 2008, Cell cycle.
[39] Carlos Caldas,et al. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.
[40] R. Cress,et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.
[41] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[42] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[43] J. Wunder,et al. Cyclin D1 and p21 is elevated in the giant cells of giant cell tumors , 2006, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[44] J. Peterse,et al. Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.
[45] I. Ellis,et al. The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.
[46] L. Marchionni,et al. hGTSE-1 Expression Stimulates Cytoplasmic Localization of p53* , 2004, Journal of Biological Chemistry.
[47] M. Lacroix,et al. Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update , 2004, Breast Cancer Research and Treatment.
[48] P. Sandy,et al. The Cell Cycle-regulated Protein Human GTSE-1 Controls DNA Damage-induced Apoptosis by Affecting p53 Function* , 2003, Journal of Biological Chemistry.
[49] R. Verardo,et al. Cell‐cycle regulation of the p53‐inducible gene B99 , 2000, FEBS letters.
[50] D. Lazarević,et al. Cloning, chromosome mapping and functional characterization of a human homologue of murine gtse-1 (B99) gene. , 2000, Gene.
[51] P. May,et al. Twenty years of p53 research: structural and functional aspects of the p53 protein , 1999, Oncogene.
[52] A. Goldhirsch,et al. Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer , 1998 .
[53] D. Lazarević,et al. A novel p53‐inducible gene coding for a microtubule‐localized protein with G2‐phase‐specific expression , 1998, The EMBO journal.
[54] A. Goldhirsch,et al. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. , 1998, European journal of cancer.
[55] J. Gehl,et al. Treatment of metastatic breast cancer with paclitaxel and doxorubicin. , 1995, Seminars in oncology.
[56] J. Milner,et al. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes , 1991, Molecular and cellular biology.